Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASCHIX:ALKBC 92 Cash-to-Debt is 4.11 as of Jun. 2026, which is 928% above its 10-year median of 0.40. GuruFocus rates CHIX:ALKBC with a GF Score™ of 92/100 and a GF Value™ of kr229.65 (Fairly Valued). Among 1,393 Biotechnology companies, Alk-Abello AS ranks worse than 56.86% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alk-Abello AS's cash to debt ratio for the quarter that ended in Jun. 2026 was 4.11.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Alk-Abello AScould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Alk-Abello AS's Cash-to-Debt or its related term are showing as below:
CHIX:ALKBc'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12 Med: 0.4 Max: 4.11
Current: 4.11
During the past 13 years, Alk-Abello AS's highest Cash to Debt Ratio was 4.11. The lowest was 0.12. And the median was 0.40.
CHIX:ALKBc's Cash-to-Debt is ranked worse than 56.86% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs CHIX:ALKBc: 4.11
Alk-Abello AS (CHIX:ALKBc) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Alk-Abello AS Cash-to-Debt Related Terms
Alk-Abello AS Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:ALKBC vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Alk-Abello AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (CHIX:ALKBC) has a Cash-to-Debt of 4.11 as of Jun. 2026. This is 928% above median its historical median of 0.40. Over the past decade, Alk-Abello AS's Cash-to-Debt has ranged from 0.12 to 4.11. According to the industry distribution chart, Alk-Abello AS ranks #792 out of 1393 companies in the Biotechnology industry, placing it in the top 56.9%.
Is Alk-Abello AS's Cash-to-Debt too high?
Alk-Abello AS's current Cash-to-Debt of 4.11 is 928% above median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 4.11. The Biotechnology industry median Cash-to-Debt is 7.03. Alk-Abello AS's value of 4.11 is 41.5% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #792 out of 1393 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #792 out of 1393 companies for Cash-to-Debt. This places Alk-Abello AS in the lower half of its industry. The industry median Cash-to-Debt is 7.03. Alk-Abello AS's value of 4.11 is 41.5% below this benchmark. Historically, Alk-Abello AS's own Cash-to-Debt has ranged from 0.12 to 4.11 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 7.03, Alk-Abello AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current Cash-to-Debt of 4.11 is 41.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Cash-to-Debt is 4.11, which is 928% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Fairly Valued. The stock's GF Value™ is kr229.65, compared to a current price of kr221.50 — trading 3.5% below its estimated fair value. The current Cash-to-Debt is 4.11, which is 928% above median its 10-year median of 0.40 and 41.5% below the Biotechnology industry median of 7.03. Alk-Abello AS's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Cash-to-Debt is 4.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be undervalued.
The current stock price of kr221.50 is trading 3.5% below its estimated GF Value™ of kr229.65.
GuruFocus considers Alk-Abello AS to be Fairly Valued.
Key valuation signals for CHIX:ALKBC:
Cash-to-Debt: 4.11 (928% above median its 10-year median of 0.40)
GF Value™: kr229.65 vs. price of kr221.50 (3.5% below fair value)
Industry Position: 41.5% below the Biotechnology median (#792 of 1393)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score
Get the complete analysis for CHIX:ALKBC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
